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Summary
Outcomes in childhood T-cell acute lymphoblastic leukaemia (T-ALL) are
steadily improving due to intensive therapy. Between 1989 and 2008, 599
children with newly diagnosed T-ALL were enrolled in two successive
European Organization for Research and Treatment of Cancer - Children’s
Leukaemia Group trials (58881 and 58951), both based on the Berlin-
Frankfurt-Munster protocol and without cranial irradiation. In the lat-
ter trial induction chemotherapy was intensified. The most important ran-
domizations were Medac Escherichia coli asparaginase versus Erwinia
asparaginase in trial 58881, and dexamethasone (6 mg/m2/day) versus pred-
nisolone (60 mg/m2/day) and prolonged versus conventional asparaginase
duration in trial 58951. 8-year event-free survival (EFS) increased from
651% to 740% in trial 58951. Improvement was most profound for
patients with white blood cell (WBC) counts <100 9 109/l and “good
responders” to prephase. Medac E. coli asparaginase was associated with
longer EFS [hazard ratio (HR) 054, P = 00015] and overall survival (HR
051, P = 00018). Induction therapy with dexamethasone did not improve
EFS compared to prednisolone. Remarkably, intensification of central ner-
vous system (CNS)-directed therapy in trial 58951 resulted in fewer bone
marrow relapses, while the incidence of CNS relapses remained low. In
summary, we showed that adequate asparaginase therapy, intensified induc-
tion treatment and intensification of CNS-directed chemotherapy can result
in an improvement of outcome in T-ALL patients with good prephase
response and initial WBC counts <100 9 109/l, representing approximately
50% of T-ALL patients.
Keywords: T-cell acute lymphoblastic leukaemia, EORTC, childhood leu-
kaemia, asparaginase, cranial radiotherapy.
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Highlights
• Medac E. coli asparaginase is superior to non-Medac
asparaginase in paediatric T-ALL.
• There is no evidence for prolonged asparaginase treatment
benefit in T-ALL patients.
• Dexamethasone induction in a dose of 6 mg/m2/day is not
superior to prednisolone 60 mg/m2/day.
• The long-term efficacy of a frontline treatment strategy
without cranial radiotherapy is demonstrated.
• Post-induction MRD ≥ 102 is associated with worse EFS
and OS, despite treatment intensification.
Childhood T-cell acute lymphoblastic leukaemia (ALL)
accounts for approximately 12–15% of newly diagnosed
ALL cases. Due to intensive therapy, outcomes in T-ALL
are steadily improving with the 5-year event-free survival
(EFS) rate increasing from 60% in the mid-nineties to more
than 80% in contemporary clinical trials (Moricke et al,
2010, 2016; Hunger et al, 2012; Matloub et al, 2016; Raetz
& Teachey, 2016). Despite advances in therapy, childhood
T-ALL still has an inferior prognosis compared to B-cell
precursor ALL (B-ALL). In particular, early disease recur-
rence with poor response to salvage therapy and treatment-
related late effects remain important challenges (Reismuller
et al, 2009, 2013).
Identification of high-risk T-ALL patients based on biolog-
ical characteristics [white blood cell (WBC) count at diagno-
sis, central nervous system (CNS)-positivity] and treatment
response, has led to treatment intensification in current pro-
tocols. Currently, the most important independent prognos-
tic determinant in T-ALL is minimal residual disease (MRD)
response at the end of induction and at the end of the con-
solidation phase. Nevertheless, the majority of relapses occurs
in patients with favourable MRD status (Schrappe et al,
2011). Unlike in B-ALL, presence of recurrent chromosomal
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translocations does not independently predict outcome (van
Grotel et al, 2006, 2008) and hence, they are not included in
patient stratification strategies. In contrast, next-generation
sequencing (NGS) has recently revealed the prognostic
impact of several oncogenetic mutational profiles (Petit et al,
2018).
Compared to children with B-ALL, T-ALL patients are at
higher risk for CNS relapse and therefore adequate prophy-
laxis and/or treatment of CNS involvement is essential. CNS
treatment includes cranial or craniospinal radiotherapy
(CRT), intrathecal (IT) therapy and systemic chemotherapy
(Richards et al, 2013). CRT has several undesirable late
effects, such as endocrine abnormalities, cognitive impair-
ment and secondary malignancies. This led the use of CRT
to be questioned in all paediatric ALL and non-Hodgkin
lymphoma (NHL) patients (Follin & Erfurth, 2016; Follin
et al, 2016; Taskinen et al, 2017). The European Organiza-
tion for Research and Treatment of Cancer - Children’s Leu-
kaemia Group (EORTC-CLG) 58832 trial was the first to
address the question of whether CRT may be removed from
ALL treatment in a randomized manner (Vilmer et al, 2000).
Medium- and high-risk B- and T-patients, without initial
CNS involvement and in complete remission (CR) after con-
solidation, received high dose methotrexate (HD MTX)
intravenously (IV) and seven IT MTX injections during late
intensification and were subsequently randomized to receive
or not prophylactic CRT before the start of maintenance
therapy. Substitution of CRT by HD MTX alone yielded not
inferior disease-free survival and CNS relapse incidences.
Consequently, CNS-directed chemotherapy replaced CRT in
the following EORTC-CLG 58881 trial (Vilmer et al, 2000).
The latter trial demonstrated that intensification of
CNS-directed chemotherapy, without CRT, is an effective
treatment of initial meningeal leukaemic involvement
and that CNS-directed chemotherapy was not associated with
an increase in isolated CNS relapse rates (Sirvent et al,
2011).
Interestingly, a meta-analysis on the use of CRT in chil-
dren with ALL showed better outcome for children with T-
ALL with slow early response in clinical trials without CRT
(Vora et al, 2016). Nevertheless, the strength of this finding
was limited by the low number of patients (n = 133) in this
sub-analysis. Conversely, another meta-analysis, which specif-
ically focused on T-ALL, found similar EFS with any of three
approaches: CRT for all patients, CRT for CNS-positive
patients or CRT omitted (Kelly et al, 2014). However, this
meta-analysis was hampered by limited sample sizes in the
included studies, so caution needs to be applied (Kelly et al,
2015). At present, the administration of CRT for T-ALL var-
ies across international paediatric oncology groups, with
some protocols including (low-dose) CRT for all patients
and some including CRT for a subset of patients, while other
protocols omit CRT entirely (Moghrabi et al, 2007; Kamps
et al, 2010; Moricke et al, 2010; Pui et al, 2010; Schrappe
et al, 2011; Mondelaers et al, 2017). In addition, no
improved survival in children with B-ALL could be demon-
strated with administration of CRT (Clarke et al, 2003;
Richards et al, 2013; Vora et al, 2016).
We sought to evaluate the long-term outcomes of children
with newly diagnosed T-ALL enrolled in two consecutive
EORTC-CLG phase III trials (58881 and 58951), both of
which used Berlin-Frankfurt-Munster (BFM)-based proto-
cols, and without front-line cranial or local radiotherapy.
Both trials investigated three questions in a randomized
manner. These were, in trial 58881: (i) Medac Escherichia coli
asparaginase versus Erwinia asparaginase (Duval et al, 2002),
(ii) addition of high-dose IV cytarabine (HD IV Ara-C) dur-
ing postinduction-consolidation therapy in increased-risk
patients (Millot et al, 2001), and (iii) addition of monthly
IV 6-mercaptopurine (IV 6-MP) to conventional continua-
tion therapy (van der Werff Ten Bosch et al, 2005), and, in
trial 58951: (i) dexamethasone versus prednisolone during
induction and maintenance (Domenech et al, 2014), (ii)
increasing the number of administrations of asparaginase
during consolidation and late intensification (Mondelaers
et al, 2017), (iii) vincristine + corticosteroid pulses or no
pulses during continuation treatment (De Moerloose et al,
2010).
Methods
Patients
From 1989 to 1998 and from 1998 to 2008, children under
18 years of age with previously untreated ALL or lym-
phoblastic NHL were included in two successive EORTC-
CLG trials, trial 58881 and 58951, respectively. In both trials,
diagnosis of ALL was defined by the presence of more than
25% blasts in the bone marrow aspirate; T-cell lineage and
T-ALL sub-classification was assessed by immunophenotyp-
ing according to the guidelines of the European Group for
the Immunological Characterization of Leukaemias (EGIL) as
previously described (Bene et al, 1995). All patients were
stratified into different risk groups as described in the
Data S1. T-ALL patients were either increased risk (IR) or
very high risk (VHR) in protocol 58881, or average risk 2
(AR2) or VHR in protocol 58951. Informed consent from
the parents or the legal guardian was provided before entry
in the study according to the Declaration of Helsinki. The
protocols were approved by the EORTC Protocol Review
Committee and by the local institutional ethical committees
in each participating centre.
Treatment
The treatment regimen of the 58881 trial was adapted from
the BFM protocol, as previously described (Vilmer et al,
2000). Main modifications introduced in the 58951 trial for
treatment of T-ALL patients were the administration of
an intensified induction protocol with cyclophosphamide
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1 g/m2 and the first HD MTX course (5 g/m2) administered
at the start of induction. Noteworthy in this trial, all patients
were randomized on day 1 or day 8 of the prephase to
receive either prednisolone (60 mg/m2/day) or dexametha-
sone (6 mg/m2/day) during induction (Domenech et al,
2014). In trial 58951, MRD monitoring was performed on
day 35 and was based on quantitative detection of leukaemic
clone-specific T-cell-receptor gene rearrangements as previ-
ously described and was considered positive if ≥102 (Cave
et al, 1994; Guidal et al, 2002).
The CNS-directed therapy consisted only of chemotherapy
as CRT was omitted in both trials (Figure S1). The main dif-
ference between CNS-directed therapies in both trials was
the type and number of IT injections. In trial 58881, IR and
VHR patients received at least 4 HD MTX courses and
received, respectively, 10 and 16 IT MTX injections, of which
6 were a combination of MTX, Ara-C and hydrocortisone
(triple IT) in VHR patients. In trial 58951, IT therapy con-
sisted of MTX only on day 1 and triple IT further on. AR2
and VHR patients received, respectively, a total of 16 and 20
IT injections and 11 and 10 HD MTX courses. Patients with
T-ALL and poor response to prephase or high levels of MRD
after induction (≥102) were eligible for haematopoietic stem
cell transplantation.
Definitions and evaluations
Definitions of complete remission and CNS disease have
been published previously (De Moerloose et al, 2010; Dome-
nech et al, 2014) and are summarized in the Data S1.
Statistics
The primary endpoints of both trials were EFS and disease-
free survival (DFS). Secondary endpoint was overall survival
(OS). Information on endpoint definitions, randomization
technique, stratification factors and statistical analysis is
included in the Data S1.
Results
Patient characteristics
Between 1989 and 2008, 599 children with newly diagnosed
T-ALL were enrolled in EORTC-CLG trials 58881 (303
patients) and 58951 (296 patients), representing 145% and
152% of all enrolled ALL patients in these trials. Detailed
patients’ characteristics are shown in Table I. The male/fe-
male ratio of the T-ALL subgroup was 29 and 24 respec-
tively and the median age at registration was 7 and 8 years,
respectively. The median WBC count was 917 and
550 9 109/l and 462% and 365% of the patients had a
WBC count ≥100 9 109/l, respectively.
At the end of prephase, 611% of patients were classified
as “good responders” in trial 58881 and 649% in trial
58951. CR after first induction was observed in 89% and
95% patients, respectively. MRD was evaluated only in trial
58951, at day 35, and was positive in 36 patients (MRD level
≥102) of which 26 showed a good prephase response
(GPR). The median follow-up in trial 58881 was 72 vs.
68 years for trial 58951.
General outcome comparison between trial 58881 and
58951 for T-ALL patients
The outcome of T-ALL patients improved markedly from
trial 58881 to trial 58951. The 8-year EFS improved from
651% to 740%, the 8-year DFS increased from 673% to
758% and the OS improved from 719% to 782%
(Table II). Relapse rates were lower in the latter trial
(58951), at 267% vs. 342% in trial 58881. The non-CNS 8-
year cumulative incidence of relapse decreased from 165%
in trial 58881 to 129% in trial 58951, whereas the 8-year iso-
lated CNS relapse incidences were similar (68% vs. 53%),
as were the 8-year overall CNS-positive relapse incidences
(109% vs. 85%).
To explore which treatment component had most impact
on the outcome of T-ALL patients, all randomized treatment
comparisons in both trials were specifically checked for the
T-ALL subgroup (Tables III and IV).
Subanalysis of trial 58881
Medac Escherichia coli asparaginase versus Non-Medac
asparaginase. In protocol 58881, a first randomization com-
pared the value of Medac E. coli asparaginase with Erwinia
asparaginase, both administered IV twice weekly for a total of
12 doses of 10 000 international units (iu) each. However,
before the randomization period started, some patients were
treated with Bayer E. coli asparaginase, and after the end of the
randomization period most patients received Medac E. coli
asparaginase, and only a few received Erwinia asparaginase,
hence, finally, we compared the outcomes of the Medac E. coli
asparaginase group (n = 209) versus Non-Medac asparaginase
group (n = 94). Outcomes were significantly better in the
Medac E. coli asparaginase group: 8-year EFS rate was 716%
vs. 521% in the Non-Medac asparaginase treated group [haz-
ard ratio (HR) 054, 99% confidence interval (CI) 032–090,
P = 00015], and 8-year OS rate was 777% vs. 596% (HR
051, 99% CI 029–090, P = 00018) (Figure S2). Complete
remission rates were similar (976% vs. 947%). The relapse
rate for the Medac E. coli asparaginase group was lower than
in the Non-Medac group (225% vs. 382%), as the isolated
CNS relapse rate (54% vs. 101%) and any CNS relapse rate
was lower (18% vs. 84%), as was the isolated + combined
bone marrow relapse rate (138% vs. 191%).
Exploratory subgroup analyses indicated that older T-ALL
patients (≥10 years old) in particular, and children with
VHR features exhibited shorter EFS in the Non-Medac
asparaginase group.
M. Hofmans et al
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No impact of high dose cytarabine during interval therapy. In
trial 58881, 653 IR ALL children were randomized to receive
or not HD IV Ara-C during interval therapy. The addition
of HD IV Ara-C to HD MTX failed to decrease the incidence
of CNS relapse or prolong DFS (HR: 106) (Millot et al,
2001). Similar findings were observed when the treatment
comparison was restricted to T-ALL patients (n = 80): 8-year
DFS rate was 674% (with HD IV Ara-C) vs. 735% (without
HD IV Ara-C).
Monthly intravenous mercaptopurine during maintenance was
associated with worse EFS. The last question of the 58881
trial evaluated the monthly addition of IV 6-MP to conven-
tional continuation therapy (van der Werff Ten Bosch et al,
Table I. Distribution of patient characteristics and treatment groups in EORTC-CLG trials 58 881 and 58 951
Trial 58881 Trial 58951
Total number of patients 2065 2038
Number of T-ALL patients 303 296
% of total ALL population 303/2065 (145%) 296/2038 (152%)
Median follow-up (95% CI) (years) 716 (657–758) 682 (607–735)
Gender
Male 225 (743%) 209 (706%)
Female 78 (257%) 87 (294%)
Age (years)
Median 70 80
Range 0–17 0–17
WBC count (9109/l)
Median 917 55
Range 03–9880 02–10000
WBC count ≥100 9 109/l 140 (462%) 108 (365%)
Mediastinal involvement 188 (620%) 138 (466%)
Gonadal involvement 7 (23%) 2 (07%)
CNS-3 22 (73%) 20 (68%)
Prephase response
Good (“GPR”) 185 (611%) 192 (649%)
Poor (“PPR”) 117 (386%) 102 (345%)
VHR
After prephase 118 (389%) 106 (358%)
After induction 126 (416%) 109 (368%)
Complete response
At any point during therapy 293 (967%) 281 (949%)
Treatment group step 1
Medac Escherichia coli asparaginase 209
Non-Medac asparaginase 94
Randomized question 2
Cytarabine 46 (152%)
No cytarabine 34 (112%)
Randomized question 3
IV mercaptopurine 53 (175%)
PO mercaptopurine 50 (168%)
Randomized question 1
Dexamethasone induction 145 (490%)
Prednisolone induction 151 (510%)
Randomized question 2
Long asparaginase 73 (247%)
Short asparaginase 74 (250%)
Randomized question 3
Corticosteroid pulses 22 (74%)
No corticosteroid pulses 23 (78%)
ALL, acute lymphoblastic leukaemia; CI, confidence interval; CNS-3, central nervous system stage 3; EORTC-CLG, European Organization for
Research and Treatment of Cancer-Children’s Leukaemia Group; GPR, good prephase response; IV, intravenously; PO, orally; PPR, poor prephase
response; T-ALL, T-cell acute lymphoblastic leukaemia; VHR, very high risk; WBC, white blood cell.
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2005). A total of 103 T-ALL patients were randomized for
this question. Both DFS and OS were significantly lower in
the IV 6-MP arm (642% and 698%, respectively) compared
to control arm (794% and 88%, respectively).
Sub-analysis of trial 58951
Dexamethasone versus Prednisolone in induction treatment: no
difference in outcome. In trial 58951, 135 patients were ran-
domized to receive dexamethasone and 145 prednisolone
during induction treatment. At a median follow-up of
68 years, 42 events were reported in the dexamethasone
group and 35 in the prednisolone group. No significant dif-
ferences in 8-year EFS and OS rates could be observed.
Distribution of the type of relapses were similar in the two
treatment groups, and subgroup exploratory analyses accord-
ing to initial WBC count, age, risk group or response to pre-
phase indicated consistent findings.
No evidence for prolonged asparaginase treatment nor pulsed
therapy. The second randomization evaluated, in average risk
patients, the value of prolonged versus standard native E. coli
asparaginase treatment during consolidation and late intensifi-
cation. A total of 147 T-ALL children were randomized. The 8-
year DFS rate was 829% in the prolonged asparaginase arm
and 821% in the standard arm (HR: 094, P = 088). Relapse
rates were comparable for both arms (164% vs. 176%), as
was the distribution of type of relapses.
Finally, trial 58951 also addressed the benefit of corticos-
teroid pulses during continuation treatment. Only 45 T-ALL
patients were randomized. Therefore, no strong conclusions
can be drawn from the present results (8-year DFS rate:
955% vs. 913% and 8-year OS rate: 955% vs. 956%).
Minimal residual disease was a strong prognostic factor. In
trial 58951, MRD was assessed at day 35 on 227 of 281
patients who reached CR: 36 had MRD ≥ 102 and 191 had
MRD < 102. In the first group, despite a switch to a more
intensive treatment, the 8-year EFS rate was 495%, far lower
than the 793% observed in the latter group, and the 8-year
OS rate was 495% vs. 856%. Of 77 patients with poor
prephase response (PPR), those with MRD ≥ 102 (n = 25)
had an 8-year EFS rate of 388%, whereas it was 730% for
those with MRD < 102 (n = 52).
Impact of CNS-directed treatment
In both trials, a group of patients (209 patients in trial 58881
and 151 in trial 58951) were treated with prednisolone
induction, Medac E. coli asparaginase and a similar BFM
backbone. The main differences in treatment between these
patient groups were the use of an intensified induction
scheme (with cyclophosphamide 1 g/m2 and HD MTX 5 g/
m2 at the beginning of phase 1A) and intensification of
CNS-directed chemotherapy in trial 58951. In this patient
subgroup, a moderate outcome improvement could be
observed between both successive trials (8-year EFS: 716%
vs. 767%) (Table V). Intensification of CNS-directed
chemotherapy in trial 58951 did not reduce the isolated or
total CNS relapse rates (54% and 84% vs. 55% and 98%)
as compared to the 58881 trial. Interestingly, a decrease in
non-CNS relapses was observed (144% vs. 105%) in trial
58951, together with a lower risk of death in complete
remission (39% vs. 15%).
In patients with GPR (n = 225), intensification of CNS-di-
rected chemotherapy resulted in an outcome improvement.
This was marked in patients with a WBC < 100 9 109/l
(n = 157): in trial 58881 (n = 85), the 8-year EFS and 8-year
OS rates were 753% and 821%, respectively, whereas in trial
58951 (n = 72), the respective rates were 846% and 930%
(Fig 1). In the subgroup of patients with GPR and
WBC ≥ 100 9 109/l (n = 68) or in those with a PPR
(n = 130), the outcomes did not improve.
Discussion
The outcome of children with T-ALL improved markedly
between the successive EORTC-CLG 58881 and 58951 trials,
with 8-year OS reaching almost 80% in the latter trial.
These results are in line with long-term outcome results
reached in other trials performed in the same era (Fig 2)
(Kamps et al, 2002, 2010; Moghrabi et al, 2007; Ballerini
et al, 2008; Moricke et al, 2008, 2010, 2016; Conter et al,
2010; Pui et al, 2010; Salzer et al, 2010; Schmiegelow et al,
2010; Silverman et al, 2010; Tsuchida et al, 2010; Hunger
et al, 2012; Petit et al, 2018). The first randomization of
trial 58881 showed that some of this improvement can be
attributed to adequate asparaginase treatment with E. coli
asparaginase. Adequate asparaginase treatment also resulted
in similar outcome improvements in patients with B-ALL
and NHL (Duval et al, 2002). Importantly, trial 58951
showed that prolongation of native E. coli asparaginase ther-
apy in consolidation and late intensification did not result
Table II. General outcome results in T-ALL patients
Trial 58881
(n = 303) (SE)
Trial 58951
(n = 296) (SE)
8-year OS 719% (26%) 782% (25%)
8-year EFS 651% (26%) 740% (26%)
8-year DFS 673% (28%) 758% (26%)
No CR reached 33% 33%
8-year cumulative incidence by event
Isolated CNS 68% 53%
Any CNS 109% 85%
Non-CNS 165% 129%
Death in CR 53% 29%
CNS, central nervous system; CR, complete remission; DFS, disease-
free survival; EFS, event-free survival; OS, overall survival; SE, stan-
dard error; T-ALL, T-cell acute lymphoblastic leukaemia.
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in an additional gain in outcome. On the contrary, pro-
longed asparaginase treatment can lead to an increased risk
of infections and allergy (Mondelaers et al, 2017).
Noteworthy, supportive care changes over time which may
also impact outcome results of successive trials. However,
regarding the EORTC-CLG trials in this study, there were no
major changes in supportive care guidelines for the partici-
pating sites. To overcome bias introduced by differences in
treatment we performed a direct comparison of patients trea-
ted with the same BFM backbone, prednisolone induction
and E. coli asparaginase. This comparison showed an addi-
tional outcome improvement in the second trial, which pre-
sumably could be attributed to the adaptation of an
intensified induction and CNS-directed treatment regimen
(protocol with HD MTX and triple IT chemotherapy consist-
ing of MTX, Ara-C and hydrocortisone). We demonstrated
that patients with GPR and WBC count at diagnosis
<100 9 109/l in particular, benefited from this intensification
with an increase in OS of more than 10%, thus reaching
93%. In contrast, in patients with PPR no outcome improve-
ment was obtained, suggesting the need for other treatment
options in these patients.
We demonstrate the long-term efficacy of a frontline treat-
ment strategy without prophylactic and therapeutic CRT. No
differences in isolated and combined CNS relapse rates were
observed compared with other contemporary trials on T-
ALL, independent of the type of CNS-directed therapy (Pui
et al, 2009; Moricke et al, 2010; Vora et al, 2016). However,
the limited number of studies on paediatric T-ALL patients
must be taken into account. Remarkably, intensification of
CNS-directed therapy in trial 58951 reduced the non-CNS
related relapse rate (bone marrow and other sites), whereas
only moderate improvement was seen on isolated or com-
bined CNS relapse rates, indicating the systemic effect of
intensification of CNS-directed therapy. This is in contrast to
evidence from the Children’s Oncology Group, who reported
more bone marrow and testicular relapses with triple therapy
compared to IT MTX alone (Matloub et al, 2006).
The in vitro cytotoxic effect of dexamethasone on lym-
phoblasts is stronger than that of prednisolone (Ito et al, 1996;
Kaspers et al, 1996). Also, dexamethasone revealed greater
CNS penetration, which is of interest in T-ALL, considering
the higher rates of CNS disease and CNS relapses (Balis et al,
1987). Therefore, several study groups have supported and
Table III. Comparison of the outcomes in EORTC-CLG trial 58881 on paediatric T-ALL
Treatment group step 1
Medac Escherichia coli
asparaginase (n = 209)
Non-Medac
asparaginase (n = 94)
Hazard ratio (99% CI) for
Medac E. coli asparaginase
versus non-Medac asparaginase P-value
8-year EFS 716% (SE: 31) 521% (SE: 52) 054 (032–090) 00015
8-year DFS 733% (SE: 31) 550% (SE: 53) 055 (037–083) 00036
8-year OS 777% (SE: 30) 596% (SE: 51) 051 (029–090) 0002
CR reached during therapy 204 (976%) 89 (947%)
Relapse 46 (225%) 34 (382%)
Isolated CNS 11 (54%) 9 (101%)
Any CNS 17 (84%) 16 (18%)
Isolated BM 23 (113%) 13 (146%)
Any BM 28 (138%) 17 (191%)
Other sites 1 (05%) 1 (11%)
Death in CR 8 (39%) 7 (79%)
Randomization 2
With Ara-C during interval
therapy (n = 46)
Without Ara-C during
interval therapy (n = 34)
Hazard ratio (99% CI)
for Ara-C versus no Ara-C
8-year DFS 674% (SE: 69) 735% (SE: 76) 135 (046–395) 047
8-year OS 761% (SE: 63) 765% (SE: 73) 104 (031–343) 094
Relapse 13 (28%) 8 (235%)
Randomization 3
Mercaptopurine IV
during maintenance (n = 53)
Mercaptopurine PO
during maintenance (n = 50)
Hazard ratio (99% CI)
for mercaptopurine IV
versus mercaptopurine PO
8-year DFS 642% (SE: 66) 794% (SE: 58) 215 (079–584) 0044
8-year OS 698% (SE: 63) 88% (SE: 46) 287 (083–984) 0021
Relapse 17 (321%) 10 (20%)
Ara-C, cytarabine; BM, bone marrow; CI, confidence interval; CNS, central nervous system; CR, complete remission; DFS, disease-free survival;
EFS, event-free survival; EORTC-CLG, European Organization for Research and Treatment of Cancer-Children’s Leukaemia Group; IV, intra-
venously; OS, overall survival; PO, orally; SE, standard error; T-ALL, T-cell acute lymphoblastic leukaemia.
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Table IV. Impact of different randomization steps in EORTC-CLG trial 58951 on paediatric T-ALL
Randomization 1
Dexamethasone
(n = 145)
Prednisolone
(n = 151)
Hazard ratio (99% CI) for dexamethasone
versus prednisolone P-value
8-year EFS 713% (SE: 38) 767% (SE: 35) 126 (070–228) 031
8-year DFS 733% (SE: 38) 782% (SE: 35) 125 (078–200) 035
8-year OS 742% (SE: 38) 841% (SE: 32) 146 (076–280) 013
Relapse 32 (221%) 29 (192%)
Isolated CNS 7 (48%) 8 (53%)
Any CNS 10 (69%) 14 (92%)
Isolated BM 19 (131%) 11 (73%)
Any BM 23 (157%) 20 (132%)
Other sites 2 (14%) 1 (07%)
Death in CR 6 (41%) 3 (2%)
Randomization 2
Prolonged asparaginase
treatment (n = 73)
Short asparaginase
treatment (n = 74)
Hazard ratio (99% CI) for prolonged
asparaginase versus short asparaginase
8-year DFS 829% (SE: 45) 821% (SE: 45) 094 (034–264) 088
8-year OS 874% (SE: 39) 919% (SE: 32) 135 (037–494) 055
Relapse 12 (164%) 13 (176%)
Randomization 3 Corticosteroid pulses (n = 22) No corticosteroid pulses (n = 23)
8-year DFS 955% (SE: 44) 913% (SE: 59) NA NA
8-year OS 955% (SE: 44) 957% (SE: 43) NA NA
Relapse 1 (45%) 2 (87%)
BM, bone marrow; CI, confidence interval; CNS, central nervous system; CR, complete remission; DFS, disease-free survival; EFS, event-free sur-
vival; EORTC-CLG, European Organization for Research and Treatment of Cancer-Children’s Leukaemia Group; IV, intravenously; NA, not
applicable (too few events reported) OS, overall survival; PO, orally; SE, standard error; T-ALL, T-cell acute lymphoblastic leukaemia.
Table V. Intensification of CNS-directed chemotherapy: comparison between patients treated with the same backbone (Medac Escherichia coli
asparaginase and Prednisolone) in EORTC-CLG trial 58881 and 58951
Trial 58881 (n = 209) Trial 58951 (n = 151)
8-year EFS 716% (SE 31) 766% (SE 35)
8-year OS 777% (SE 30) 821% (SE 32)
8-year cumulative incidence by event
Isolated CNS 54% 55%
Any CNS 84% 98%
Non-CNS 144% 105%
Death in CR 39% 15%
GPR n = 126 n = 99
8-year EFS 767% (SE 38) 816% (SE 39)
8-year OS 847% (SE 32) 889% (SE 32)
WBC count <100 9 109/l n = 85 n = 72
8-year EFS 753% (SE 47) 846% (SE 43)
8-year OS 821% (SE 42) 930% (SE 31)
WBC count ≥100 9 109/l n = 41 n = 27
8-year EFS 797% (SE 64) 736% (SE 86)
8-year OS 902% (SE 46) 780% (SE 79)
PPR n = 82 n = 48
8-year EFS 645% (SE 53) 676% (SE 70)
8-year OS 675% (SE 57) 705% (SE 71)
CNS, central nervous system; CR, complete remission; EFS, event-free survival; EORTC-CLG, European Organization for Research and Treatment
of Cancer-Children’s Leukaemia Group; GPR, good prephase response; PPR, poor prephase response; SE, standard error; WBC, white blood cell.
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Fig 1. EFS according to WBC count at diagnosis in patients with a “good response to prephase”, receiving similar background therapy in trial
58881 and 58951. Event-free survival (EFS) according to white blood cell (WBC) count at diagnosis (<100 9 109/l [continuous line] vs.
≥100 9 109/l [dashed line]) in (A) patients receiving Medac Escherichia coli asparaginase in trial 58881 and (B) patients randomized to pred-
nisolone treatment in trial 58951. Both patient groups received a similar Berlin-Frankfurt-Munster-backbone, prednisolone induction and Medac
E. coli asparaginase treatment. A marked outcome improvement could be seen in patients with a diagnostic WBC count <100 9 109/l. O,
observed events; N, number.
Fig 2. Qualitative impact of ‘end year of study inclusion’ on survival rates in children with T-ALL. Every study, depicted by a solid dot, is
labelled with the study name. x-axes refers to ‘the end year of study-inclusion’ of each study, the y-axes illustrate the 5-year* probability of event-
free survival. The standard error of each study is depicted and the size of the dot is a measure of the number of patients included in the study.
Both EORTC-CLG trials are depicted with solid dots. *The 8-year EFS is shown For both EORTC-CLG trials (58881 and 58951). AIEOP, Associ-
azione Italiana di Ematologia e Oncologia Pediatrica; ALL, acute lymphoblastic leukaemia; COG, Children’s Oncology Group; DCLSG, Dutch
Childhood Leukaemia Study Group; DCOG, Dutch Children’s Oncology Group; DFCI, Dana Farber Cancer Institute; EORTC-CLG, European
Organization for Research and Treatment of Cancer-Children’s LeukaemiaGroup; FRALLE, French Acute Lymphoblastic Leukaemia Study Group;
(IC)-BFM, (intensive chemotherapy) Berlin-Frankfurt-Munster; NOPHO, Nordic Society for Paediatric Haematology and Oncology; UKALL;
United Kingdom acute lymphoblastic leukaemia.
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incorporated the use of dexamethasone in paediatric T-ALL
trials (Mitchell et al, 2005; Moricke et al, 2016). Surprisingly,
our long-term outcome results show that dexamethasone
(6 mg/m2/day) is not superior to prednisolone induction
(60 mg/m2/day) in T-ALL patients, for both GPR and PPR
patients. These data are in line with a review from Teuffel et al
(2011), which could not demonstrate superior long-term OS
with dexamethasone induction in ALL children. In contrast,
the Associazione Italiana di Ematologia e Oncologia Pedi-
atrica-BFM 2000 trial has shown that administration of a
higher dose of dexamethasone (10 mg/m2) in children with T-
ALL and good early treatment response resulted in prolonged
EFS and OS and in relapse reduction (Moricke et al, 2016).
Despite marked improvement of outcome in T-ALL
patients over time, the prognosis is still worse compared to B-
ALL. Early disease recurrence and low numbers of successful
remission re-induction can account for these differences.
Therefore, future efforts should focus on fast identification
and treatment intensification for patients at higher risk for
relapse, and discovery of novel therapies for relapsed patients.
The AIEOP-BFM-ALL 2000 trial was the first to incorporate
MRD based on immunoglobulin and T-cell receptor gene rear-
rangements as polymerase chain reaction targets for stratifica-
tion. They showed that MRD negativity on day 33 was the
most favourable prognostic factor, MRD positivity (≥103) at
day 78 the most important predictor for relapse, and that
MRD also had an impact on the incidence of relapses with
extramedullary components (Schrappe et al, 2011). In trial
58951, patients with MRD ≥ 102 were switched to the VHR
group and received a more intensive treatment. Despite this,
our results demonstrated that MRD levels ≥102 on day 35 are
associated with worse EFS and OS. In another trial, we showed
that NOTCH pathway activation (due to NOTCH1 and
FBXW7 mutations) was associated with favourable early treat-
ment response (Clappier et al, 2010). In this respect, Petit et al
(2018) revealed that MRD in combination with oncogenetic
mutations can identify T-ALL patients with worse prognosis.
Therefore, incorporation of these prognostic features in future
trials and adaptation of therapy is warranted.
In summary, we showed that adequate asparaginase (and not
prolonged) therapy during induction, intensified induction
treatment and intensification of CNS-directed chemotherapy can
improve the outcome in patients with GPR and initial WBC
counts <100 9 109/l, representing approximately 50% of T-ALL
patients. Also, we demonstrated that dexamethasone in a lower
dose of 6 mg/m2/day is not superior to prednisolone induction.
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